Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics


Gracell Biotechnologies Inc. (GRCL): $2.14

-0.03 (-1.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRCL to Watchlist
Sign Up

Industry: Beverages


Ranked

of

in industry

GRCL Stock Price Chart Interactive Chart >

Price chart for GRCL

GRCL Price/Volume Stats

Current price $2.14 52-week high $5.69
Prev. close $2.17 52-week low $1.68
Day low $2.09 Volume 50,300
Day high $2.19 Avg. volume 161,382
50-day MA $2.65 Dividend yield N/A
200-day MA $3.08 Market Cap 144.85M

Gracell Biotechnologies Inc. (GRCL) Company Bio


Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.


GRCL Latest News Stream


Event/Time News Detail
Loading, please wait...

GRCL Latest Social Stream


Loading social stream, please wait...

View Full GRCL Social Stream

Latest GRCL News From Around the Web

Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | December 12, 2022

Gracell Biotech's Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates

Gracell Biotechnologies Inc (NASDAQ: GRCL) announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. Patients in the study achieved a 100% overall response rate (ORR) and 100% minimal residual disease (MRD) negativity in all dose levels. Related: Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims. A

Yahoo | December 12, 2022

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the clinical data from its ongoing Phase 1, investigator-initiated trial (IIT) in China evaluating FasTCAR-enabled GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. Data has been presented in an

Yahoo | December 10, 2022

Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims

HC Wainwright initiated coverage on Gracell Biotechnologies Inc (NASDAQ: GRCL) with a Buy rating and a price target of $6. The China-based company is focused on developing autologous and allogeneic CART cell therapies to treat cancer. The analyst notes that Gracell will submit an IND for a potentially registrational study in the U.S. for GC012F (lead program) for relapsed/refractory multiple myeloma by year-end. Related: Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients.

Yahoo | December 8, 2022

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

Yahoo | November 23, 2022

Read More 'GRCL' Stories Here

GRCL Price Returns

1-mo 2.88%
3-mo -34.56%
6-mo -39.38%
1-year -38.68%
3-year N/A
5-year N/A
YTD -6.96%
2022 -61.92%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7183 seconds.